Toward Personalized Targeted Therapeutics: An Overview

Area of Science:

• Neuro-oncology
• Personalized Medicine
• Molecular Oncology

Background:

• The field of neuro-oncology is shifting towards personalized medicine, aiming to tailor treatments based on individual patient and tumor characteristics.
• Advances in molecular analysis of glioblastoma (GBM) have spurred optimism for developing personalized targeted therapies.
• Despite increased understanding of GBM's molecular complexity, effective therapeutic strategies face significant hurdles.

Purpose of the Study:

• To review the challenges hindering the development of effective targeted therapeutic strategies for glioblastoma.
• To highlight the need for innovative approaches in clinical trials to overcome these obstacles.

Main Methods:

• This review synthesizes current knowledge on the molecular complexity of glioblastoma.
• It identifies and discusses key challenges in translating molecular insights into clinical practice.
• The review emphasizes the limitations of current clinical trial designs.

Main Results:

• Key challenges identified include disease heterogeneity, patient variability (clinical and genomic), limited effective treatments, and inefficiencies in clinical trials.
• Specific obstacles encompass drug delivery issues, and challenges in clinical trial support and patient accrual.
• The review underscores the gap between molecular understanding and successful clinical application.

Conclusions:

• Overcoming the complexities of glioblastoma requires innovative and adaptive clinical trial designs.
• Accelerating the development of targeted therapies is essential to improve outcomes for glioblastoma patients.
• A concerted effort is needed to address the multifaceted challenges in neuro-oncology drug development.